Member Info for Timster

https://www.bbc.co.uk/news/uk-59486165

he has no idea if they detect Omnicron though!

not all LFT's are born equal though...

see above, give them a call (although they blanked me)

bizzare angle of deramp. investors have eyes you know that yeah?

not sure what you're looking at

https://www.medusa19.com/en/

Avct have announced this, its not new news

Manufacturing process has been transferred to Abingdon Health and the validation batches
are now entering production.
• Abingdon Health could add a further 1-2 million tests per month capacity

https://avacta.com/wp-content/uploads/2021/09/Avacta-Group-plc-Interim-Results-Final.pdf

nice, so 3 weeks ish we have second manufacturer online.

would hope HUA and Desktop review will also be completed this year.

Happy Christmas, HO HO HO!!

got a bit confused with Affimers and Precision there. But nice to see how confident they seem in their Avacta investment

Final results will be on the way soon and they will include some LFT sales.

Courtesy of GMCC, thought it deserved its own thread to make it clear that we are funded

https://youtu.be/NZHIxNQT4Tg?t=230

CFO states cash runway sufficient through to 2023 ( without including any LFT sales ) .
AVA6000 +other projects including "Enables expansion of recruitment into ongoing phase I study to include eligible US patients upon opening of clinical sites in early 2022" already bugeted . If that means just more sites will be added to the 6 already mentioned in UK and assume they stick with approx P1 trial @ 80 patients then costs per patient already covered .

Avacta continue to expand their diagnostics team so surely expect incoming revenues to flow end 2021 /grow throughout 2022 + any affimer therapeutics licence /stage payments etc will also boost cash coffers .
So cash ok for AVA6000
However who knows what will happen in late 2022/2023 for Avacta ?
Nasdaq listing - buy out -affimers into clinic - If fund raise required at a later stage not a problem if at premiuim to SP at the time needed . Market cap value rather undervalued at the moment so all to play for still in my opinion - exciting times .

quite pricey by the looks
https://www.sofpromed.com/how-much-does-a-clinical-trial-cost

Am I right in saying that PCR will be easy to confirm as they can use the synthetic samples?

but for our lateral flow test we will need live virus which is much harder to come by? Although because of where the Affimer binds its highly likely to detect omnicron.

interesting spot losta but it is mentioned in the results presentation

https://avacta.com/wp-content/uploads/2021/09/Avacta-Group-plc-Interim-Results-Final.pdf

slide 14 and 15

Agreed, that's what everyone is waiting for short term. Avaxxxx are the long term plays (obviously)

Started in August and was always due to run into 2022

Phase 1a
Objective:Assess safety and tolerability of AVA6000; determine MTD and/or recommended dose for further development
Approximately 4 Cohorts to achieve MTD
15 to 20 patients
Patient Population: Locally advanced and/or metastatic pancreatic, colorectal, non-small cell lung, breast, head and neck (SCCHN), soft tissue sarcoma, ovarian and bladder cancer

Page 15
https://avacta.com/wp-content/uploads/2021/09/Avacta-Group-plc-Interim-Results-Final.pdf

Yep 28th Feb 2022

Praise be

sorry . missing
https://www.linkedin.com/company/advena-ltd.
https://www.advenamedical.com/

did we know Advena ltd are our EC reps?

https://www.linkedin.com/company/advena-ltd

its on the affidx label, not sure I've heard of them before

on a serious note though, how have Bioserve sold me these? they obviously don't care about the desktop review